Start-Low-Go-Slow Protocols for MCAS, ME/CFS, and Autoimmune Disease

Yoon Hang “John” Kim, MD, MPH, FAAMA

Board-Certified Preventive Medicine | Integrative & Functional Medicine | LDN Research Trust Presenter

I’ve been prescribing low dose naltrexone for over two decades. In that time I’ve learned that the patients who do worst on standard protocols are very often the patients who need LDN the most. They show up with mast cell activation syndrome (MCAS), myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), long-standing autoimmune disease, mold or Lyme histories, post-viral illness, or some combination. They’re the canaries.

And like the canaries miners once carried into coal shafts, their bodies are picking up on something the rest of the room doesn’t feel yet. That sensitivity is information. The clinical task is to honor it.

Who is a “canary” patient?

“Canary” isn’t a formal diagnosis. It’s a description of a clinical pattern I see all the time. Canary patients tend to share most of the following:

• Years (often decades) of complex, layered illness rather than a single recent diagnosis.
• Multiple drug or supplement intolerances — they react to things other patients tolerate without a thought.
• A pattern of paradoxical reactions: small doses cause big symptoms; “starter” doses feel like overdoses.
• MCAS features (flushing, hives, food and odor sensitivities, GI symptoms, dysautonomia).
• Post-exertional malaise — even mild activity is followed by a crash, often delayed by a day or two.
• A profound loss of resilience — colds linger, stressors don’t bounce off, sleep doesn’t restore.

What ties these features together, in my view, is a depleted endorphin reserve. The body has been running on emergency reserves for so long that it has very little buffer left. Introducing anything that touches the opioid system — even a small dose of LDN — can feel destabilizing.

Endorphin reserve, in plain language

Endorphins are your body’s own opioid-like chemicals. They help with pain, mood, sleep, immune balance, and resilience under stress. Think of them as the vitality currency your nervous system spends every day. When you’re healthy, the account refills overnight. When you’ve been ill for a long time, you’re running an overdraft.

In Traditional Chinese Medicine this kind of deep reserve is called Jing. In Ayurveda it’s Ojas. Different languages, the same idea: a measurable-by-feel sense of how much vital capacity you have left in the tank.

LDN works in part by encouraging your body to make more of its own endorphins and to use them more effectively. That’s wonderful for a patient with reasonable reserves to start with. For a canary patient with very little reserve, the same nudge can feel like running an engine that’s already overheating.

This is why I almost never start a canary patient at 1.5 mg. Often I start a hundred times lower, sometimes a thousand times lower. The goal isn’t a “bigger” dose — it’s the smallest dose that wakes up the system without overwhelming it.

The Kim LDN Optimal Dose Questionnaire™

Before prescribing the first dose, I ask every patient five questions. I’ve refined this in clinic over many years, and I now call it the Kim LDN Optimal Dose Questionnaire™. It’s not a lab test. It’s a structured way of estimating how much endorphin reserve you have to work with — and therefore where to start.

I’m not assigning a numerical score. I’m listening to the texture of the answers. A patient who has been ill for fifteen years, sleeps poorly, runs on caffeine to make it to lunch, crashes for three days after a short walk, and stopped working two years ago is in an entirely different place from a patient with a recent autoimmune diagnosis who still hikes on the weekends. Both may benefit from LDN. They should not start at the same dose.

Start-low-go-slow: titration tables for canary patients

Most LDN information online describes a fast climb to 4.5 mg over two to four weeks. That’s a reasonable starting point for a more robust patient. For a canary patient it can be a setup for a flare. Below is how I actually think about the dose ladder.

Table 1. The LDN dose ladder

At 1 microgram, naltrexone barely tickles the opioid system. It can still act as a hormetic signal — a small biological nudge that asks the body to make more endorphins without overwhelming the receptors it’s trying to support.

Table 2. Where I start, and how slowly I climb

What the science actually says (the honest version)

LDN is one of my favorite tools. It is not magic. Anyone selling it as a sure thing is overselling.

On the encouraging side, the early fibromyalgia studies by Younger and colleagues at Stanford showed about a 29% reduction in pain on 4.5 mg of LDN compared to roughly 18% on placebo. A retrospective analysis at the Mayo Clinic of 115 patients found that about 65% of those on LDN for chronic pain reported some benefit. In ME/CFS, a retrospective analysis from Finland of 218 patients reported that nearly three-quarters experienced a positive response to 3.0–4.5 mg LDN over an average follow-up of about 1.7 years.

On the sobering side, the FINAL trial published in Lancet Rheumatology in 2024 — the largest randomized controlled trial of LDN in fibromyalgia to date — did not show a statistically significant pain reduction over placebo at 6 mg. A larger proportion of patients on LDN achieved at least a 30% pain reduction than on placebo, and memory symptoms improved, but the primary endpoint was negative. That deserves to be said out loud, not hidden in a footnote.

Two truths can sit side by side. Some patients respond beautifully to LDN. Roughly one in three patients does not respond to standard protocols at all. The canary population sits right at that fault line — which is exactly why dose strategy matters so much.

What this looks like by condition

Mast cell activation syndrome (MCAS)

MCAS patients are often the most reactive of all. In a published BMJ case report, a severely affected patient with both POTS and MCAS could not tolerate ordinary LDN escalation; her physician started her at 1 mg at night rather than climbing to 4.5 mg. That ultra-low dose improved her pain, mood, sleep, flushing, food and odor sensitivities, and limb tingling — and became a core part of a regimen that returned her to a near-normal life.

In my own practice, almost every MCAS patient starts in the microgram range. We usually pair LDN with a true mast cell stabilization plan (a clean low-histamine baseline, ketotifen, cromolyn, sometimes methylene blue with metabolic support), as I describe more fully in the LDN Primer. LDN by itself is rarely enough; LDN inside a thoughtful MCAS protocol is often transformative.

Myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS)

ME/CFS patients almost always have profound post-exertional malaise. They cannot afford to “push through” an LDN side effect. If a 1.5 mg starting dose causes vivid dreams, insomnia, or a flare, they may be set back for weeks.

Research from Cabanas, Marshall-Gradisnik, and colleagues at the National Centre for Neuroimmunology and Emerging Diseases has shown that naltrexone may help restore impaired ion channel function (TRPM3) in natural killer cells from ME/CFS patients. That gives a plausible biological reason behind the clinical signal Polo and colleagues reported in their 218-patient series. It also tells us we’re working on a delicate system. Slow titration honors that.

Autoimmune disease

For autoimmune patients — Hashimoto’s, lupus, rheumatoid arthritis, multiple sclerosis, Crohn’s disease, psoriasis, and others — LDN’s appeal is its capacity to calm immune dysregulation without the side-effect burden of conventional immunosuppression. Small randomized trials have suggested quality-of-life benefits in MS, and a placebo-controlled trial in active Crohn’s disease showed improvement in mucosal healing on LDN.

Autoimmune patients who are otherwise functional often tolerate standard 1.5 → 4.5 mg titration well. Autoimmune patients with overlapping MCAS, ME/CFS, mold, or Lyme histories almost never do. The same diagnosis can hide two very different metabolic situations. That’s why the questionnaire matters more than the diagnostic label.

What you should expect on a canary-patient protocol

1. It will feel slow. That is the protocol working, not the protocol failing. A canary protocol can take three to six months to find a stable, effective dose, sometimes longer.
2. Vivid dreams and short-term sleep changes are common, even at very low doses, and usually settle. Nightmares in patients with significant trauma history are a reason to pause and reassess.
3. Symptoms may flutter before they improve. Mast cell symptoms, fatigue, or pain can wobble in the first few days after each dose change.
4. If you feel worse and it doesn’t resolve in a few days, the answer is almost always to step down, not to power through. Drop to the last well-tolerated dose and stay there.
5. Roughly a third of patients won’t respond meaningfully to LDN at any dose. If you’re in that group, you’re not failing the medicine — the medicine is showing you that the work is somewhere else.

LDN is a tool, not the whole toolbox

Canary patients almost never get fully well on LDN alone. In my experience, LDN often does what nothing else has done — it lowers the noise enough that other treatments finally have a chance to work. That might mean mast cell stabilization, a careful look at mold or Lyme, mitochondrial and metabolic support, hormone balance, sleep repair, trauma-informed nervous-system work, or whatever your particular root causes turn out to be.

If you’d like the longer version of this framework — including the dosing categories, how I assess endorphin reserve in detail, when to consider higher-dose naltrexone, and the MCAS stacking protocol — it lives in the free LDN Primer at the Low Dose Naltrexone Support Group, and is expanded with case material in my book Low Dose Naltrexone: Two Decades of Clinical Observation and Review of Current Research.

About the author

Yoon Hang “John” Kim, MD, MPH, FAAMA is a board-certified preventive medicine physician practicing integrative and functional medicine. He completed Dr. Andrew Weil’s Integrative Medicine Fellowship at the University of Arizona and is an Institute for Functional Medicine Certified Practitioner. Dr. Kim has prescribed LDN since the early 2000s, has presented at multiple LDN Research Trust conferences, and has authored three books on LDN. He sees patients via telemedicine through Direct Integrative Care in Iowa, Illinois, Missouri, Georgia, Florida, and Texas, and in person at Hill Country Integrative Medicine in Fredericksburg, Texas.

Clinical practice: directintegrativecare.com    Physician mentoring: yoonhangkim.com

References

Bruun, K. D., Christensen, R., Amris, K., Vaegter, H. B., Blichfeldt-Eckhardt, M. R., Bye-Møller, L., Holsgaard-Larsen, A., & Toft, P. (2024). Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: A randomised, double-blind, placebo-controlled trial. The Lancet Rheumatology, 6(1), e31–e39. https://doi.org/10.1016/S2665-9913(23)00278-3

Cabanas, H., Muraki, K., Balinas, C., Eaton-Fitch, N., Staines, D., & Marshall-Gradisnik, S. (2019). Validation of impaired transient receptor potential melastatin 3 ion channel activity in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients. Molecular Medicine, 25(1), 14. https://doi.org/10.1186/s10020-019-0083-4

Cabanas, H., Muraki, K., Eaton-Fitch, N., Staines, D. R., & Marshall-Gradisnik, S. (2021). Potential therapeutic benefit of low dose naltrexone in myalgic encephalomyelitis/chronic fatigue syndrome: Role of transient receptor potential melastatin 3 ion channels in pathophysiology and treatment. Frontiers in Immunology, 12, 687806. https://doi.org/10.3389/fimmu.2021.687806

Driver, C. N., & D’Souza, R. S. (2023). Efficacy of low-dose naltrexone and predictors of treatment success or discontinuation in fibromyalgia and other chronic pain conditions: A fourteen-year, enterprise-wide retrospective analysis. Biomedicines, 11(4), 1087. https://doi.org/10.3390/biomedicines11041087

Kim, Y. H. (2025). Low dose naltrexone: Two decades of clinical observation and review of current research.

Parkitny, L., & Younger, J. (2017). Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines, 5(2), 16. https://doi.org/10.3390/biomedicines5020016

Polo, O., Pesonen, P., & Tuominen, E. (2019). Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Fatigue: Biomedicine, Health & Behavior, 7(4), 207–217. https://doi.org/10.1080/21641846.2019.1692770

Sharafaddinzadeh, N., Moghtaderi, A., Kashipazha, D., Majdinasab, N., & Shalbafan, B. (2010). The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: A randomized placebo-controlled trial. Multiple Sclerosis Journal, 16(8), 964–969. https://doi.org/10.1177/1352458510366857

Smith, J. P., Bingaman, S. I., Ruggiero, F., Mauger, D. T., Mukherjee, A., McGovern, C. O., & Zagon, I. S. (2011). Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: A randomized placebo-controlled trial. Digestive Diseases and Sciences, 56(7), 2088–2097. https://doi.org/10.1007/s10620-011-1653-7

Toljan, K., & Vrooman, B. (2018). Low-dose naltrexone (LDN) — Review of therapeutic utilization. Medical Sciences, 6(4), 82. https://doi.org/10.3390/medsci6040082

Weinstock, L. B., Brook, J. B., Myers, T. L., & Goodman, B. (2018). Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Reports, 2018, bcr-2017-221405. https://doi.org/10.1136/bcr-2017-221405

Younger, J., & Mackey, S. (2009). Fibromyalgia symptoms are reduced by low-dose naltrexone: A pilot study. Pain Medicine, 10(4), 663–672. https://doi.org/10.1111/j.1526-4637.2009.00613.x

Younger, J., Noor, N., McCue, R., & Mackey, S. (2013). Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis & Rheumatism, 65(2), 529–538. https://doi.org/10.1002/art.37734

Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33(4), 451–459. https://doi.org/10.1007/s10067-014-2517-2

Disclaimer. This article is educational and reflects Dr. Kim’s clinical experience and reading of the published literature; it is not medical advice and does not create a physician–patient relationship. LDN dosing — and especially microgram or nanogram dosing — should be guided by a clinician who knows your full history.